

PROMOTION RECOMMENDATION  
THE UNIVERSITY OF MICHIGAN  
MEDICAL SCHOOL  
DEPARTMENT OF INTERNAL MEDICINE

Sami N. Malek, M.D., associate professor of internal medicine, with tenure, Department of Internal Medicine, Medical School, is recommended for promotion to professor of internal medicine, with tenure, Department of Internal Medicine, Medical School.

Academic Degrees:

M.D.                                      1991    University of Hamburg-Eppendorf, Germany

Professional Record:

2011-present      Associate Professor of Internal Medicine, University of Michigan  
2004-2011          Assistant Professor of Internal Medicine, University of Michigan

Summary of Evaluation:

Teaching: As a physician scientist, Dr. Malek's teaching efforts are spread over many different learners within the Division of Hematology/Oncology including fellows, internal medicine residents, medical students in clinics as well as clinical fellows, post-doctoral fellows, and undergraduate students in his laboratory. His philosophy on teaching was shaped by his own educational experiences and focuses on challenging each student to achieve a higher level of individual competency through role modeling, instruction, motivation for self-directed learning and lectures as well as probing existing knowledge and deficiencies. Dr. Malek has mentored and trained many fellows in Hematology/Oncology who have all advanced to their next desired career level, many whom were hired by the University of Michigan. In recognition of Dr. Malek's teaching and mentoring expertise, he was recently invited to join the University of Michigan R01 Boot Camp Program as a coach. Additionally, he has been invited five times in the last five years to summarize advancing knowledge in chronic leukemia at the American Society of Hematology (ASH) review CME course.

Research: Dr. Malek's scholarly work focuses on building translational research projects in selected hematological malignancies. Currently, he serves as the principal investigator on four large innovative translational trials in Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML) and B-cell Non-Hodgkin's Lymphoma (B-NHL). He also oversees two lymphoma repositories and large biospecimen banks as well as elaborate clinical/genomic databases. Dr. Malek's efforts in creating these resources have been emulated at other universities and have also served many other investigators at the University of Michigan interested in research on primary human tumors. His laboratory has achieved national and international recognition for their work in translational genomics and hematological malignancies; the latter evidenced by invitations to speak at more than 30 invited lectures, elected to membership on the ASH Scientific Committee on Lymphoid Neoplasia, the Scientific Committee of the Society of Hematological Malignancies (SOHO) and the American Society of Clinical Investigation (ASCI). Since his appointment to associate professor in 2011, Dr. Malek has published 26 peer-

reviewed publications, many in high impact journals such as *Blood*, *PLoS One*, and *Clinical Cancer Research*. His research is funded by two active R01 grants and a Leukemia and Lymphoma Society of America (LLSA) Scholar Award as well as industry and philanthropic support.

Recent and Significant Publications:

Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, Talpaz M, Kaminski M, Li C, Shedden K, Malek SN: Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. *Blood* 118:3051-3061, 2011.

Parkin B, Ouillette P, Li Y, Keller J, Lam C, Roulston D, Li C, Shedden K, Malek SN: Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. *Blood* 10;121:369-377, 2013.

Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Fox H, Jacobi K, Saiya-Cork K, Bixby D, Lebovic D, Roulston D, Shedden K, Sabel M, Marentette L, Cimmino V, Chang AE, Malek SN: Mutations in linker histone genes HIST1H1 B, C, D and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. *Blood* 123:1487-1498, 2014.

Yildiz M, Li H, Bernard D, Amin N, Ouillette P, Jones S, Saiya-Cork K, Parkin B, Jacobi K, Shedden K, Wang S, Chang AE, Kaminski MS, Malek SN: Activating STAT6 mutations in follicular lymphoma. *Blood* 125:668-679, 2015.

Amin N, Seymour EK, Saiya-Cork K, Parkin B, Shedden K, Malek S: A Quantitative analysis of subclonal and clonal gene mutations pre- and post-therapy in chronic lymphocytic leukemia. *Clin Cancer Res* 2016 Apr 8 pii: Clincanres.3103.2015. [Epub ahead of print]

Service: On the institutional level, Dr. Malek has served on many committees since 2011 including the Cancer Center Protocol Review Committee, the University of Michigan Senate Assembly, the Medical Affairs Advisory Committee, and the Cancer Center Research Committee. In addition to these institutional committees, Dr. Malek has served as an invited grant reviewer for European funding agencies and as an ad hoc reviewer for many NIH study sections and special emphasis panels, including program project grants and SPOR grant review panels. Nationally, he is currently serving on the ASH Scientific Committee on Lymphoid Neoplasia and the Scientific Committee of the Society of Hematological Malignancies. Clinically, Dr. Malek serves as a staff attending physician in the hematological malignancy group with special expertise in the diagnosis and treatment of CLL and also MDS/AML and selected lymphomas. He attends on the inpatient hematological malignancy service for four weeks every year. His clinical expertise in CLL and MDS/AML and selected lymphomas has directly contributed to the success in the build-up of translational trials with over 1,000 individuals enrolled.

### External Reviewers:

Reviewer A: “From 2011 to the present he has published 25 manuscripts, 12 as senior author, with 11 of the 12 having already been cited more than [*sic*] twenty times, and as a collaborator has an additional 3 manuscripts during this time that have been cite more than 100 times....The high number of citation of his work reflects the high standard and general interest of his studies...I think the most important work for which he is the senior author is in fact the body of work over several years focused on the genomics of CLL.”

Reviewer B: “I have continued to follow Dr. Malek’s career since his promotion 5 years ago and cannot think of anyone more deserving of a promotion to full professor than him. Dr. Malek represents a very accomplished researcher in that he now has 54 publications being an impressive first or last author on 36 of them....He is well funded with grants including two R01’s and holds numerous patents.”

Reviewer C: “...I would rank Dr. Malek’s scholarly work and impact among the top 1% of physician-scientist[s] working in hematology in the United States today. Dr. Malek is a Principal Investigator on two NIH R01 grants and has active funding from the Leukemia and Lymphoma Society (LLS Scholar Award). His research productivity is reflected by over fifty peer-reviewed manuscripts in top tier cancer journals....His work has received greater than 2,200 citations. He is nationally recognized as a leader in the field of leukemia and lymphoma genomics and has made significant contributions to the field and was elected to membership of the ASCI in 2016.... He is addressing important clinical translational questions and has developed a national and international reputation for his cutting-edge research.”


Reviewer D: “Since his promotion to Associate Professor in 2011, his research has continued to contribute to his growing national and international reputation for insightful genomic analysis of hematological malignancies....The high quality of this research is also reflected in Dr. Malek’s selection as a Leukemia & Lymphoma Society Scholar (2011-2016) as well as his recent election to the American Society of Clinical Investigation.”

Reviewer E: “He is a widely sought lecturer both nationally and internationally and is very involved in major journals as a reviewer and on scientific grant study sections both here in the United States and in Europe. He now has significant experience in mentoring both fellows and post-doctoral fellows as well as being a very busy teacher and educator at his current academic institution....I also believe him to be a team player with strong desires to develop an even more expansive program in CLL genomics. Your consideration of his promotion to the rank of Professor with Tenure (Instructional Track) is most appropriate given his vast accomplishments and would certainly be done at my institution.”

Reviewer F: “Dr. Malek’s CV shows clear evidence of dedication and strong engagement in teaching. He supervises residents and fellows on teaching rounds and morning report, gives a number of didactic sessions and has mentored a number of predoctoral students and postdoctoral fellows....In my experience...Dr. Malek would be promoted to Professor because of his consistent and impactful publication and funding record, solid participation in teaching and national and international reputation.”

Summary of Recommendation:

Dr. Malek is regarded as an expert in his field of hematological malignancies with recognition on the national and international level. He has maintained an impressive track record of both funding and publications since his promotion to associate professor and is expected to maintain this success in the future. He is an excellent clinician and has been recognized for his teaching and mentoring for both students and his peers. It is for these reasons that I recommend Sami N. Malek, M.D. for promotion to professor of internal medicine, with tenure, Department of Internal Medicine, Medical School.



---

Marschall S. Runge, M.D., Ph.D.  
Executive Vice President for Medical Affairs  
Dean, Medical School

May 2017